62
Participants
Start Date
March 31, 2015
Primary Completion Date
August 31, 2017
Study Completion Date
August 31, 2017
NL201
mIL-11:5μg/kg，subcutaneous administration once daily for 10 days,beginning 24 h after chemotherapy；
NL201
mIL-11:7.5μg/kg，subcutaneous administration once daily for 10 days,beginning 24 h after chemotherapy；
NL201
The optimal dosing dose NL201，subcutaneous administration once daily for 10 days,beginning 24 h after chemotherapy.
rhIL-11
rhIL-11(25μg/kg)，subcutaneous administration once daily for 10 days,beginning 24 h after chemotherapy.
Fudan University Shanghai Cancer Center, Shanghai
Beijing Cancer Hospital, Beijing
The Third Affiliated Hospital of Harbin Medical University, Harbin
The First Hospital of Jilin University, Changchun
Tianjin Medical University Cancer Institute and Hospital, Tianjin
Beijing Northland Biotech. Co., Ltd.
INDUSTRY